• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic and endocrine effects.

作者信息

van Wayjen R G, van den Ende A

机构信息

Department of Internal Medicine, Prinsengracht Hospital, Amsterdam, The Netherlands.

出版信息

Exp Clin Endocrinol Diabetes. 1995;103(4):241-51. doi: 10.1055/s-0029-1211357.

DOI:10.1055/s-0029-1211357
PMID:7584530
Abstract

The effects and side effects of long-term treatment with cyproterone acetate (CPA) are described. Hammerstein's reverse sequential regimen (10 days 100 mg CPA, 21 days 50 micrograms ethinylestradiol (EE)) was used in most cases, although postmenopausal and hysterectomized women received 50 mg CPA/day continuously as monotherapy. The degree of androgenization was assessed in 143 of a total group of 188 women treated from 1968 to the present. The results of the treatment were good or very good in about 75% of hirsutism patients and in more than 90% of acne patients. Adverse events were recorded in 23% of cases. Most were mild and transient, and caused discontinuation of the therapy in only 9% of patients. From this population representing all cases treated and analysed retrospectively, a subgroup of patients was selected for a prospective investigation. Thirty-five patients with good response to CPA and longlasting therapy were included into this 2-year follow-up study; of these, 24 had previously received CPA for 5 or more years, 9 for more than 10 years and 2 for more than 15 years. Treatment in these patients consisted of 5 different regimens of various doses of CPA combined with EE and CPA alone in order to evaluate possible effects of concomitant estrogen treatment as well as a possible dose- or time-dependency of potential side effects. Clinicochemical, metabolic and endocrine parameters were determined at the start and end of the study. The hematological and clinicochemical parameters were within the normal ranges. There was a slight decrease of glucose tolerance and a moderate increase of insulin and C peptide after oral glucose loading. The effects of CPA and EE on lipometabolism were slight and apparently dependent on the dose of CPA and the therapeutic regimen. No suppression of adrenal function or of responsiveness to ACTH was seen. Fasting prolactin levels and serum prolactin concentrations after provocation with metoclopramide did not show any gross deviations. Sonography of the breast and liver did not show any abnormalities apart from adenofibrosis or mastopathy in 2 patients. In conclusion, CPA with or without EE was in our hands an effective and safe method of long-term treatment of hirsutism and/or acne in women.

摘要

相似文献

1
Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic and endocrine effects.
Exp Clin Endocrinol Diabetes. 1995;103(4):241-51. doi: 10.1055/s-0029-1211357.
2
[Medium-dose oral cyproterone acetate therapy in women with moderate androgenization. Results of a multicenter double-blind study].[中等剂量醋酸环丙孕酮口服治疗中度雄激素化女性。一项多中心双盲研究的结果]
Geburtshilfe Frauenheilkd. 1984 Jan;44(1):47-52. doi: 10.1055/s-2008-1036425.
3
[Clinical use of antiandrogens in the female].
Gynakologe. 1980 Mar;13(1):1-17.
4
Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study.氟他胺与螺内酯加乙炔雌二醇/醋酸环丙孕酮治疗多毛症的临床疗效比较:一项随机对照研究。
Adv Ther. 2008 Apr;25(4):321-8. doi: 10.1007/s12325-008-0039-5.
5
Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate.含0.030毫克炔雌醇/2毫克地诺孕素的复方口服避孕药与安慰剂及0.035毫克炔雌醇/2毫克醋酸环丙孕酮相比治疗丘疹脓疱型痤疮的疗效
Contraception. 2009 Apr;79(4):282-9. doi: 10.1016/j.contraception.2008.10.010. Epub 2008 Dec 16.
6
Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance.罗格列酮与乙炔雌二醇/醋酸环丙孕酮单药及联合治疗超重多囊卵巢综合征伴胰岛素抵抗的女性。
Hum Reprod. 2006 Jan;21(1):121-8. doi: 10.1093/humrep/dei312. Epub 2005 Sep 30.
7
[The effectiveness of oral cyproterone acetate in combination with ethinylestradiol in acne tarda of the facial type].醋酸环丙孕酮联合炔雌醇治疗面部迟发性痤疮的疗效
Ann Endocrinol (Paris). 1999 Sep;60(3):157-66.
8
[Treatment of virilized women with intramuscular administration of cyproterone acetate].[采用醋酸环丙孕酮肌肉注射治疗男性化女性]
Geburtshilfe Frauenheilkd. 1983 May;43(5):281-7. doi: 10.1055/s-2008-1036893.
9
A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.炔雌醇(0.035毫克)与醋酸环丙孕酮(2毫克)联合用于多囊卵巢综合征治疗的新研究
Acta Eur Fertil. 1986 Jan-Feb;17(1):19-25.
10
[A new ovulation inhibitor antiandrogen].一种新型排卵抑制剂抗雄激素
J Bras Ginecol. 1984 Mar;94(3):91-7.

引用本文的文献

1
Hormonal treatment of acne vulgaris: an update.寻常痤疮的激素治疗:最新进展
Clin Cosmet Investig Dermatol. 2016 Sep 2;9:241-8. doi: 10.2147/CCID.S114830. eCollection 2016.
2
The efficacy of oral isotretinoin versus cyproterone compound in female patients with acne and the triad of cutaneous hyperandrogenism: A randomized clinical trial.口服异维A酸与环丙孕酮复方制剂治疗女性痤疮及皮肤高雄激素三联征的疗效:一项随机临床试验。
Adv Biomed Res. 2014 Dec 31;3:262. doi: 10.4103/2277-9175.148236. eCollection 2014.
3
Profiling and hormonal therapy for acne in women.
女性痤疮的特征分析与激素治疗
Indian J Dermatol. 2014 Mar;59(2):107-15. doi: 10.4103/0019-5154.127667.
4
Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth.青少年多囊卵巢综合征的当前诊断和治疗方法。
Horm Res. 2007;68(5):209-17. doi: 10.1159/000101538. Epub 2007 Apr 5.